Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Target Price at $43.00

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $43.00.

Several brokerages have issued reports on BCAX. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. TD Cowen assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating for the company. Cantor Fitzgerald assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating on the stock. Rodman & Renshaw started coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company. Finally, Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price target on the stock.

Bicara Therapeutics Trading Down 4.4 %

BCAX stock opened at $18.27 on Thursday. The business’s 50 day simple moving average is $20.65. Bicara Therapeutics has a 1-year low of $16.01 and a 1-year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Equities analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current year.

Hedge Funds Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BCAX. Cinctive Capital Management LP acquired a new stake in Bicara Therapeutics in the third quarter valued at about $229,000. Barclays PLC acquired a new position in shares of Bicara Therapeutics during the third quarter valued at about $255,000. Jane Street Group LLC acquired a new position in Bicara Therapeutics during the 3rd quarter valued at about $309,000. Teachers Retirement System of The State of Kentucky bought a new stake in Bicara Therapeutics during the third quarter worth $358,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Bicara Therapeutics in the 3rd quarter worth about $462,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.